

camurus®

Company presentation

September 2026



Forward looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations, and it may cause any or all our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus' ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements.

Camurus snapshot



Rapidly growing commercial stage company

Leader in opioid dependence treatment.
Commercial infrastructure in Europe and Australia, building out to the US



Unique FluidCrystal[®] technology platform

Commercially validated with a broad range of applications



Advancing late-stage pipeline with blockbuster potential

Prospect for multiple new approvals in rare disease and oncology indications



Strong operational and financial performance

Sustainable profitability since 2022

Listed on Nasdaq
Stockholm
Ticker: CAMX
300+ employees

Significant recent progress

PIPELINE

Oczyesa® launched

- EU and UK approvals in 2025
- First launch in Germany in November 2025 – now also available in Sweden

PARTNERSHIPS

Lilly long-acting incretins

- Entered license collaboration in 2025 – recently expanded to include amylin agonists
- Entered partnership with Gubra on long-acting PTH analog

STRONG FINANCIALS

Double-digit growth

- High profitability – operating margin 42% in Q2 2026
- SEK 4.1 billion cash position

Continued growth of Buvidal® across Europe and Australia


Brixadi® gaining share in a growing US market

Positive POSITANO Phase 2b and CAM2056 Phase 1b clinical results


Improved sustainability performance and ratings
New HQ and labs

Growth and high profitability

Revenues



Operating result



Positive 2026 outlook*

Revenues

SEK 2.6 – 2.9 billion

Midpoint + 21% vs. 2025

Operating result


SEK 0.9 – 1.2 billion

Midpoint + 20% vs. 2025

* Excl. potential licensing revenues from development partnerships

FluidCrystal[®] long-acting release technology

- ✓ Easy and convenient administration
- ✓ Rapid onset & long-acting release
- ✓ Controlled by composition, liquid crystal phase structure and biodegradation
- ✓ Applicable across substance classes
- ✓ Compatible with prefilled syringes, auto-injector pens, and other advanced devices
- ✓ Manufacturing by standard processes



Commercial portfolio





Buvidal® – effective opioid dependence treatment

Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over¹



Buvidal has demonstrated significant benefits to patients and society

- ✓ Superior treatment outcome and patient satisfaction¹⁻⁴
- ✓ Blocks subjective opioid effects from first dose²
- ✓ Reduces treatment burden and improve quality of life^{4,5}
- ✓ Decrease risk of diversion, misuse and pediatric exposure^{6,7}
- ✓ Provides cost savings⁸

¹Lofwall et al. *JAMA Int. Med.* 2018;178(6): 764-773; ²Walsh et al, *JAMA Psychiatry* 2017;74(9):894-902; ³Frost, M., et al. *Addiction.* 2019;114(8):1416-1426. doi: 10.1111/add.14636; ⁴Lintzeris, N., et al. *JAMA Network Open.* 2021;4(5):e219041. doi:10.1001/jamanetworkopen.2021.9041, ⁵Barnett et al *Drug and Alcohol Dependence* 2021; <https://doi.org/10.1016/j.drugalcdep.2021.108959>; ⁶EPAR for Buvidal; ⁷Dunlop, A. J., et al. *Addiction.* 2021. <https://doi.org/10.1111/add.15627>; ⁸Dunlop, A. Oral presentation at CPDD June 2020.





Strengthened market leadership for Buvidal

77,000 patients in treatment at end-June 2026

19% in-market growth Q2 2026 vs. Q2 2025

>80% share of LAI segment in Australia


Strong performance in Europe

- High growth in Q2 2026 in Nordics, Germany, Spain and France
- Improving sales in the UK as new NHS funding becomes available

Good growth opportunities going forward

- Price approvals in further European markets
- Significant growth potential in larger European markets
- Other LAI product withdrawing from Australia by end-2026
- Goal of more than 100,000 patients in treatment by 2027

Buvidal sales





Brixadi® gaining share in growing US market

+42% net revenue growth Q2 2026 vs Q2 2025


+20% net revenue growth Q2 vs Q1 2026

>30% share of US LAIB segment (e-units)¹

Gaining share in an expanding market

- Estimated 6-7 million people with opioid dependence in the US, ~2 million in treatment²⁻⁵
- US LAIB segment now ~USD 1.2 billion annualized
 - ~10% of total OUD buprenorphine market – substantial conversion runway
- Braeburn increasing investments in patient-facing activities
- Estimated peak sales potential above USD 1 billion⁶

Brixadi royalty and unit share



Oczyesa® – our new long-acting octreotide subcutaneous depot



5-fold bioavailability vs octreotide LAR with potential for improved efficacy^{1,2,5}



Convenient and easy self-administration to improve patients' treatment experience¹⁻³



Autoinjector pen with a hidden, thin (22-gauge) needle^{1,4}



Stored at room temperature and ready to use^{1,4}

Autoinjector pen



Oczyesa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.¹

Oczyesa launch momentum in Europe

Sales in Germany continued according to plan

- Continued positive patient and physician feedback
- Focus for H2 2026: broaden adoption toward a double-digit share of SRL-treated acromegaly patients


Expanding across wave 1 markets

- Available in Sweden – first patients treated, launch meeting in September 2026
- Formulary process ongoing in the UK – first outcomes expected Q3 2026

Building the evidence base

- ACROINNOVA data presented at ECE 2026 (700 symposium audience)
- Real-world data study initiated

Oczyesa wave 1 countries in acromegaly




Significant opportunity in wave 1 markets

- Est. 3,000 – 5,000 acromegaly patients currently on SRL SoC¹
- Additional 500 - 800 new patients start treatment every year¹
- Market research indicate 30-60% willing to switch to Ocyesa²

R&D pipeline



Broad and diversified R&D pipeline



Other clinical stage programs include CAM2032 (prostate cancer), CAM2043 (Raynaud's phenomenon and PAH⁴), CAM2047 (CINV⁵), and CAM4072⁶ (genetic obesity disorders)



Octreotide SC depot, CAM2029

CAM2029 is a long-acting octreotide in development for three serious rare disease indications

- ✓ Acromegaly
- ✓ Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
- ✓ Polycystic liver disease (PLD)

Designed for enhanced efficacy and patient convenience vs. current somatostatin receptor ligands (SRLs)

CAM2029 designed to address key limitations of current first-generation SRLs


- ✓ Ready-to-use FluidCrystal technology
- ✓ Rapid onset and long-acting octreotide release¹
- ✓ 5-fold octreotide bioavailability vs Sandostatin LAR with potential for improved efficacy¹⁻³
- ✓ State-of-the-art, pre-filled autoinjector pen enabling convenient patient self-administration
- ✓ Subcutaneous administration with thin needle (22-gauge, 12.5mm)
- ✓ Room temperature storage




CAM2029 provides high SRL exposure

~5x higher octreotide plasma exposure for CAM2029 vs. Sandostatin LAR

- CAM2029 octreotide plasma levels in the range of immediate release octreotide



Comprehensive CAM2029 clinical program




SORENTO Phase 3 study of CAM2029 in GEP-NET progressing

Randomized, active-controlled Phase 3 study

- Randomized, multi-center, open-label, active-controlled Phase 3 study of CAM2029 vs. long-acting octreotide or lanreotide in patients with GEP-NET
- Fulfills regulatory requirements for safety and efficacy

Patient population

- Patients with confirmed, advanced and well-differentiated GEP-NET of Grade 1 to Grade 3 – majority Grade 2



Primary endpoint


- Superiority in progression free survival, PFS, vs. standard of care (first-line medical treatment), hazard ratio 0.65
- Assessed after 194 documented PFS events

Secondary endpoints include

- Overall survival
- PROs (e.g., treatment satisfaction, quality of life)
- Safety

Recruitment completed end 2023

- 332 patients enrolled across 12 countries, exceeded randomization target (302)



CAM2029 – one drug, three indications

Acromegaly

Approved in EU and UK

MARKETED / FILED

- ✓ Self-administered, patient-friendly profile
- ✓ Marketed as Oczyesa in Europe – first launch in Germany
- ✓ CRL for US NDA in June 2026, all points raised addressed
- ✓ Multiple presentations at ACE, ECE and ENDO
- US approval decision – PDUFA date 18 Dec 2026

GEP-NET

SORENTO Phase 3 advancing

PHASE 3

- ✓ Largest randomized SRL study in GEP-NET to date
- ✓ Active-controlled, head-to-head against standard of care
- ✓ ENETS medical symposium in Krakow 4-6 March
- Target number of 194 PFS events exp. Q4 2026
- Top-line Phase 3 results

PLD

POSITANO Phase 2 positive

PHASE 2 COMPLETE

- ✓ Positive Phase 2 results – primary endpoint met
- ✓ End-of-phase 2 meeting with FDA completed
- ✓ POSITANO oral presentation EASL, Barcelona, 27–30 May
- Next steps informed by FDA guidance and extension data

CAM2029

– differentiated therapy, large market potential

Acromegaly — Est. peak sales*
\$180 – 280 million

GEP-NET — Est. peak sales*
\$1.5 – 2+ billion

Shared benefits	Acromegaly	GEP-NET
• ~5X bioavailability vs. octreotide LAR • SC self-injection vs. clinic IM injection • Autoinjector pen — optimal convenience • Room temperature storage – no cold chain • Validated FluidCrystal delivery platform	• EU and UK approved (Oczyesa) • Superior biochemical control vs placebo • Improved symptom control and quality of life vs. standard-of-care at baseline • Launched in Germany — available in Sweden • Pricing and reimbursement in UK, NO	• Largest SRL trial in NET (SORENTO, n=332) • Head-to-head vs. standard-of-care SRLs • Primary endpoint: PFS superiority (HR 0.65) • Start data readout expected Q4 2026 • Addressable SRL market >USD 4B globally

Pipeline: Polycystic liver disease (PLD) — positive Phase 2b results (2025) · Additional indications under evaluation



Early-stage programs

Several early-stage programs advancing


- ✓ CAM2056 once-monthly semaglutide
- ✓ Partnership with Lilly for long-acting incretins
- ✓ Collaboration with Gubra on long-acting PTH analog

Phase 1b study of once-monthly semaglutide


Randomized Phase 1b study comparing CAM2056 with once-weekly semaglutide (Wegovy®)

– Assessing pharmacokinetics, pharmacodynamics and safety in 80 participants with overweight or obesity

Study design



Greater reductions in body weight levels with CAM2056



CAM2056 and early R&D programs

CAM2056

Monthly depot of semaglutide

- ✓ Positive Phase 1b data announced in Nov 2025
 - Superior body weight and HbA1c reduction vs Wegovy
 - Comparable safety profile
- ✓ Type B meeting with the FDA program
- ✓ Completion of regulatory submission package for Phase 2b study
- Start Phase 2b study H2 2026
- Final product design (including autoinjector pen device)

Partner programs

Long-acting incretins with Lilly

- ✓ Partnership entered Jun 2025
- ✓ Covers dual GLP-1/GIP and triple GLP-1/GIP/glucagon agonists with FluidCrystal
- ✓ Progressing according to plan
- ✓ Lilly exercised option to include amylin agonists

Long-acting PTH analog with Gubra

- ✓ Partnership entered Dec 2025
- ✓ Development progressing according to plan



License agreement with Lilly on long-acting incretins

Partnership focused on long-acting therapies based on FluidCrystal and Lilly's proprietary drug compounds

- Lilly obtained license to research, develop, manufacture and commercialize long-acting incretin products based on FluidCrystal
- Includes up to four Lilly proprietary drug compounds within the exclusivity scope:
 - Dual GIP and GLP-1 receptor agonists
 - Triple GIP, glucagon and GLP-1 receptor agonists
 - An option to include amylin receptor agonists

Camurus eligible to receive:

- Up to \$290 million in license fees, development and regulatory milestone payments
- Up to \$580 million in sales-based milestone payments
- Tiered mid-single digit royalties on global net product sales



Strategic priorities going forward



Clear path to continued value creation

Commercial execution excellence

- Strengthen market leadership in opioid dependence treatment
- Launch continuing in acromegaly
- Secondary manufacturer



Advancing pipeline with high potential

- SORENTO readout in GEP-NET
- Start of Phase 2b for CAM2056
- US approval decision for Oclaiz
- New and expanded clinical programs



Partnerships and M&A opportunities

- Progressing partnerships with Lilly and Gubra
- Potential new transactions



Supported by strong operations and financial performance

- Sustainable profitability since 2022
- SEK 4.1 billion cash position



Camurus AB | Rydbergs torg 4, SE-224 84 Lund, Sweden
P +46 46 286 57 30 | info@camurus.com | camurus.com

Shareholders and analyst coverage

Shareholders as of 31 August	Number of shares	% of capital	% of votes
Sandberg Development AB	18,280,692	30.2	30.2
Fourth Swedish National Pension Fund	2,791,193	4.6	4.6
Handelsbanken fonder	1,730,543	2.9	2.9
Vanguard	1,633,896	2.7	2.7
Fredrik Tiberg, CEO	1,542,000	2.6	2.6
Swedbank Robur Fonder	1,463,757	2.4	2.4
AMF Pension & Funds	1,428,339	2.4	2.4
Avanza Pension	1,305,405	2.2	2.2
Camurus AB	1,050,000	1.7	1.7
Capital Group	1,010,726	1.7	1.7
Second Swedish National Pension Fund	902,211	1.5	1.5
Afa Försäkring	848,912	1.4	1.4
Third Swedish National Pension Fund	839,142	1.4	1.4
Two Seas Capital	814,573	1.4	1.4
Carnegie Fonder	810,000	1.3	1.3
Other shareholders	24,107,795	39.8	39.8
In total	60,559,184	100.0	100.0

Analysts

DNB Carnegie

Erik Hultgård

Handelsbanken

Suzanna Queckbörner

Jefferies

Shan Hama

Nordea

Viktor Sundberg

Pareto

Filip Wiberg

Stifel

Oscar Haffen Lamm

SEB

Christopher Uhde

ABG Sundal Collier

Georg Tigalonov-Bjerke

Van Lanschot Kempen

Romy O'Connor

Danske Bank

Gonzalo Artiach Castañon

Redeye*

Richard Ramanius

Creating sustainable impact

Advancing innovation and access to medicines

- Camurus' commitment to improving the lives of patients with severe and chronic diseases has a clear positive sustainability impact

Creating value while minimizing environmental footprint

- Delivering patient and societal benefit while minimizing environmental footprint and risks across the value chain

Focused strategy across the value chain

- Structured efforts across four areas: patients, people, planet, and responsible business

Leading ESG performance

- Improved ESG ratings highlights sustainability, ethics, and risk management

Learn more at camurus.com/sustainability



ESG rating results:

Score 19.7
Low risk

by Morningstar Sustainability

MSCI
ESG RATINGS



CCC	B	BB	BBB	A	AA	AAA
-----	---	----	-----	---	----	-----



Significant growth opportunity for Buvidal in larger European countries

High access markets


- Australia, Nordics, Scotland and Wales
 - Average patient share 35% of total 100,000 treated patients
 - Continued double-digit growth expected in 2026

High potential, limited access markets

- England, Germany, France and Spain
 - Single digit patient share of total 500,000 patients in treatment
 - Steady growth of ~20% expected in 2026
 - Large upside if funding situation is resolved in UK or France and when renumeration change is implemented in Germany

Expansion markets

- Including IT, PT, AT, CH, BE, IE, SI and MENA
 - Single digit patient shares of total 100,000 patients
 - Expected growth in double-digit range in 2026 from smaller base



Focus on high-potential, limited access markets

Policy affair programs gaining wide stakeholder support

UK

- Recent reports supporting increased uptake of LAIB
- Demand increasing for expanded access
- Wide stakeholder support from CJ, internal affairs and health depts



Germany

- Change in remuneration system proposed
- Growing support for LAIB access
- e.g. Bavarian parliament workshop



France

- New parliament reports proposing better access to LAIB
- National and regional funding being secured




Spain

- Buvidal label restriction (2nd line) now removed
- Initiatives to facilitate transfer from methadone to LAIB



Highlight of German opportunity in acromegaly

~2,000 target patients in Germany¹⁻⁵



Market potential in Germany

- SRL acromegaly annual sales ~EUR 50 million⁶

German physician's positive to Oczyesa profile

"It will make it possible to treat acromegaly much more effectively and with fewer complications."

"Very positive and very different from all the other treatments we have for acromegaly. Hopeful. Very, very good I would say."

High interest to switch to treatment with Oczyesa

- Physician indicate that initially 30 – 60% of patients are suitable for switching to Oczyesa⁷
- Promising initial uptake since 1 November 2025 launch


Positive results from ACROINNOVA 1 – CAM2029 provided robust biochemical control

ACROINNOVA 1 study design

- 24-week, randomized, double blind, placebo-controlled Phase 3 study

Patient population


- Biochemically controlled on first-generation SRL*



Superiority achieved

- 77.2% vs. 37.5% patients with $\text{IGF-1} \leq 1 \text{ ULN}$ with CAM2029 versus placebo, $p=0.00018$

IGF-1 levels well controlled



CAM2029 improved

- Treatment convenience
- Acromegaly quality of life
- Patient satisfaction

CAM2029 was well tolerated

- Safety profile comparable to well established profile for first generation SRLs
- Most AEs were mild or moderate and transient injection site reactions and gastrointestinal side-effects
- No serious reactions related to CAM2029


Positive topline results from ACROINNOVA 2

ACROINNOVA 2 study design


- 52-week, open-label safety study with further extension

Patient population

- New patients; uncontrolled or controlled with $\text{IGF-1} < 2 \times \text{ULN}$
- Patients who completed ACROINNOVA 1



Improved acromegaly symptoms with CAM2029



ACROINNOVA 2 results

- Reinforcing long-term safety and effectiveness in ACROINNOVA 1
- Increased response rate from SoC baseline in new recruited patients
- Roll-over placebo patients from ACROINNOVA 1 regained IGF-1 control with CAM2029

Improved patient reported outcomes for CAM2029 vs standard-of-care baseline

- Treatment satisfaction
- Quality of life
- Injection experience


POSITANO met the primary endpoint in double-blind randomized part

POSITANO study design

- 53-week randomized, placebo-controlled, three-arm study
- Open label extension for 120 weeks (ongoing)

Patient population


- Patients with symptomatic PLD (isolated or associated with ADPKD)



Primary endpoint met

- 4.3% reduction in height-adjusted total liver volume vs placebo at week 52, $p=0.044$

Reduction in total liver volume



CAM2029 improvements of:

- PLD symptoms (PLD-S score vs baseline)
- Total liver cyst volume growth
- Kidney volume in patients with PLD associated with ADPKD

CAM2029 generally well tolerated

- Safety profile consisted with other injectable SRLs
- No new or unexpected safety issues identified
- High treatment retention
- All eligible patients entered extension phase

Positive top-line results from Phase 1b study of CAM2056

Faster and greater reduction of body weight, A1c and fasting glucose

- ✓ CAM2056 produced superior dose-dependent PD response
 - Weight change from baseline to Day 85 was -9.3% for CAM2056 10 mg versus -5.2% for weekly semaglutide per label; treatment difference -4.1% (-7.1%, -1.1%), $p=0.008$
 - Mean A1c change from baseline to Day 85 for CAM2056 10 mg was -0.44%; treatment difference vs weekly semaglutide -0.32% (-0.50%, -0.14%), $p<0.001$
- ✓ Comparable C_{max} at four times the dose of weekly semaglutide (Wegovy®)
 - Prolonged time to C_{max} and extended release, consistent with monthly dosing

CAM2056 well tolerable with safety profile consistent with weekly semaglutide

- ✓ Similar safety and tolerability to weekly semaglutide dosed according to label
 - No new or unexpected safety events
 - The most common adverse events were mild to moderate and transient GI events
 - Limited number of injection site reactions; all mild and transient
- ✓ Dose escalation well tolerated up to highest initiation in group 5
- ✓ Few discontinuations; 1-2 per CAM2056 group* vs 2 for weekly semaglutide